18.07.19
Anders Hinsby: "I am writing to personally share the news that I will be resigning my position as Orphazyme’s Chief Executive Officer effective October 1, 2019..."
Read more15.07.19
This year the NPUK Interactive Workshop will take place on the 20th September at Wyboston Lakes, Bedfordshire - and will as ever be a fantastic opportunity for clinicians, health professionals and scientists working in the Niemann-Pick field to meet together under one roof...
Read more05.07.19
Our Annual Family Conference and Interactive Workshop on Niemann-Pick Diseases is the largest event in the NPUK calendar, bringing together affected individuals, families, health and research professionals under one roof...
Read more11.06.19
Orphazyme plans to meet with the US Food and Drug Administration (FDA) to discuss the pathway forward during the Summer and will provide an update after it has received written comments from the FDA...
Read more03.06.19
CTD Holdings, Inc. (OTCQB: CTDH)("CTD" or the "Company"), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it closed its previously announced private placement of securities with a group of institutional and accredited investors that included directors and officers of the Company.
Read more
